HSCI and Stock Connect - Biotech Stocks Now Eligible; Inclusion & Exclusion Possibilities
Hang Seng Indexes Company (HSIL) reviews the constituents of the Hang Seng Composite Index (HSCI) on a half yearly basis in March and September...
992 Views
Alphamab Lock-Up Expiry: Promising Clinical Data Since IPO, Worth a Reverse Inquiry
Alphamab's lock-up expiry for cornerstone investors will come on June 12th, 2020. Upon lock-up expiry USD 686 million worth of stake held by...
541 Views
Kintor Pharma IPO Initiation: To Screen, or Not to Screen?
Kintor Pharmaceutical (1762178D CH) is a clinical-stage drug developer with a focus on potential first-in-class and best-in-class drugs for cancers...
354 Views
Akesobio: Trading Debut, Valuation Scenario Analysis
Akeso Biopharma Inc (9926 HK) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...
558 Views
Akesobio (康方生物) IPO Trading: Action Post Near Zero Allocation
Akesobio, a China-based biotech company, raised USD 314 million at HKD 16.18 per share. The deal has attracted strong demands from both retail...
526 Views